Short answers, pulled from the story.
Genentech was founded in 1976 by venture capitalist Robert A. Swanson and biochemist Herbert Boyer. Boyer had co-demonstrated in 1973 that restriction enzymes could be used to cut and recombine DNA, and Swanson contacted him to turn that technique into a company.
Genentech is historically regarded as the world's first biotechnology company because it was the first organization to express a human gene in bacteria, producing the hormone somatostatin in 1977, and to commercially develop a genetically engineered human therapeutic, synthetic human insulin approved by the FDA in 1982.
Roche fully acquired Genentech in March 2009 by purchasing all remaining shares it did not already control for approximately $46.8 billion, making Genentech a wholly owned subsidiary. Roche had first acquired a majority stake in 1990 through F. Hoffmann-La Roche AG.
The University of California, San Francisco sued Genentech in 1990, claiming the company had used technology covered by a 1982 UCSF patent to develop Protropin, its growth hormone drug, without authorization. Genentech denied the claim, and in November 1999 the two parties settled for $200 million after a jury found the patent valid but could not determine whether Protropin was derived from UCSF research.
Genentech's first marketed drug was Protropin, a supplementary growth hormone for children with growth hormone deficiency, approved in 1985. Before that, the company had licensed synthetic human insulin to Eli Lilly in 1982, but Lilly manufactured and sold that product under the brand name Humulin.
Tecentriq, the brand name for atezolizumab, is an anti-PD-L1 antibody approved in 2016 to treat advanced bladder cancer and metastatic non-small cell lung cancer. It was the first drug of its class to receive FDA approval for those indications, with the bladder cancer approval granted on an accelerated basis based on promising phase II results.